Results 141 to 150 of about 63,048 (236)

Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]

J Antimicrob Chemother
Sader HS, Papp-Wallace KM, Kimbrough JH, Debabov D, Mendes RE, Castanheira M.   +5 more
europepmc   +1 more source

Ceftazidime-avibactam in elastomeric pump for vascular graft infection: a case report. [PDF]

Infez Med
Berruti M, Pincino R, Laurenda D, Sciolè K, Migliorati M, Forni N, Malerba G, Farinella ST, Casella L, Cenderello G.   +9 more
europepmc   +1 more source

Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis. [PDF]

Clin Infect Dis
Gatti M, De Paola R, Giorgi B, Pea F.
europepmc   +1 more source

Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants

De novo infections caused by ceftazidime/avibactam-resistant KPC variants are rarely reported. We characterize the evolution of a KPC-8-producing Klebsiella pneumoniae strain involved in a primary infection without previous ceftazidime/avibactam ...
Mateo-Vargas, María Alejandra, Rodríguez-Pallares, Salud, Galán-Sánchez, Fátima, Arca-Suárez, Jorge, López Cerero, Lorena, Rodríguez-Iglesias, Manuel   +5 more
core   +1 more source

Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run

Background: Therapeutic drug monitoring (TDM) is becoming an increasingly recommended approach for assessing optimal pharmacokinetic/pharmacodynamic (PK/PD) target attainment of ceftazidime/avibactam.
Gatti, Milo, Viale, Pierluigi, Pea, Federico   +2 more
core   +1 more source

A Ten-Year Trend of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> From United States Medical Centers: Results From the INFORM Surveillance Program (2015-2024). [PDF]

Open Forum Infect Dis
Sader HS, Mendes RE, Lock J, Papp-Wallace KM, Castanheira M.   +4 more
europepmc   +1 more source

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study [PDF]

Chen-Huan Yu,1 Mao-Song Tsai,2 Chun-Hsing Liao,2 Chia-Jui Yang2 1Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; 2Division of Infectious Disease, Department of Internal Medicine, Far Eastern Memorial Hospital, New
Tsai MS, Yu CH, Yang CJ, Liao CH
core  

Global epidemiology of carbapenem-resistant <i>Pseudomonas aeruginosa</i>. [PDF]

JAC Antimicrob Resist
Gottesdiener LS, Satlin MJ.
europepmc   +1 more source

Emergence of carbapenemase KPC-14 in an <i>Escherichia coli</i> isolate: a case report. [PDF]

JAC Antimicrob Resist
Fontán García-Rodrigo L, Díez Aguilar M, Sevillano Tripero L, Semiglia Chong MA, Cardeñoso Domingo L.   +4 more
europepmc   +1 more source

<i>In vitro</i> potency of novel ertapenem/zidebactam combination (WCK 6777) against carbapenemase-producing Enterobacterales collected across India. [PDF]

JAC Antimicrob Resist
Bakthavatchalam YD, Bonomo R, Egli A, Puthan R, Shankar A, Krishnamoorthy S, Nagvekar V, Ekadashi RS, J S, Rajan S, Rodrigues C, Jayaprada R, Manesh A, Veeraraghavan B.   +13 more
europepmc   +1 more source